You are here
Further examination of the reducing transition rate in ultra high risk for psychosis samples: The possible role of earlier intervention
B. Nelson, H.P. Yuen, A. Lin, S.J. Wood, P.D. McGorry, J.A. Hartmann, A.R. Yung
Schizophrenia Research, Volume 174, Issue 1-3, July 2016, Pages 43 - 49
An early intervention for psychosis and its effect on criminal accusations and suicidal behaviour using a matched-cohort design
Jason R. Randall, Dan Chateau, Mark Smith, Carole Taylor, James Bolton, Laurence Katz, Elaine Burland, Alan Katz, Nathan C. Nickel, Jennifer Enns, Marni Brownell, The PATHS Equity Team.
Schizophrenia Research, Volume 176, Issue 2-3, October 2016, Pages 307 - 311
Usefulness of the CAPE-P15 for detecting people at ultra-high risk for psychosis: Psychometric properties and cut-off values
Akvile Bukenaite, Jan Stochl, Nilufar Mossaheb, Miriam R Schäfer, Claudia M Klier, Jana Becker, Monika Schloegelhofer, Konstantinos Papageorgiou, Angel L Montejo, Debra A Russo, Peter B Jones, Jesus Perez, G Paul Amminger
Schizophrenia Research, In Press, Corrected Proof, Available online 27 February 2017, Available online 27 February 2017
Alexis C. Edwards, Silviu-Alin Bacanu, Tim B. Bigdeli, Arden Moscati, Kenneth S. Kendler
Schizophrenia Research, Volume 176, Issue 2-3, October 2016, Pages 136 - 140
Safety and tolerability of long-acting injectable versus oral antipsychotics: A meta-analysis of randomized controlled studies comparing the same antipsychotics
Fuminari Misawa, Taishiro Kishimoto, Katsuhiko Hagi, John M. Kane, Christoph U. Correll
Schizophrenia Research, Volume 176, Issue 2-3, October 2016, Pages 220 - 230
Armida Mucci, Eleonora Merlotti, Alp Üçok, André Aleman, Silvana Galderisi
Invited Commentary by Dr Armida Mucci:
1. Can you describe the concept of persistent negative symptoms?
Persistent negative symptoms (PNS) are those negative symptoms that are present for at least six months, in subjects with attenuated positive symptoms, low depression scores and low extrapyramidal side effects of medications. There are operationalized criteria to reliably assess PNS.
2. Why are they so important?
They are so important because they predict poor functioning and quality of life, and represent an unmet need of schizophrenia treatment, while other negative symptoms, which fluctuate, are probably secondary to other aspect of the syndrome (e.g., a patient can be apathetic or anhedonic because of depression) and are amenable to treatment (the paper we are reviewing is part of a special issue of Schizophrenia Research which includes reviews on Secondary Negative symptoms, Treatment, Assessment, etc.). PNS do not respond to available treatments and should be the target of new treatment development.
3. What are the biological markers of persistent negative symptoms?
The search for biological markers of PNS is still in progress. A review of data indicated reduced gray matter in the temporal lobe and altered white matter in the frontal lobe. Unfortunately, these studies used different definitions of PNS and did not attempt to divide them in the two domains of Avolition and Expressive deficit which might have different biological markers.
4. What is your take-home message?
My take home message is that clinicians and researchers have to devote more attention than in the past to the assessment and characterization of PNS. A replicated finding is that PNS are related to the duration of untreated psychosis, so there is room for improved prevention of these devastating symptoms with early interventions. Furthermore, the reduction of heterogeneity of PNS by dividing them in persistent Avolition and Expressive deficit might foster a decisive progress in our understanding of these symptoms to give impulse to effective treatment development.
Characterization of premorbid functioning during childhood in patients with deficit vs. non-deficit schizophrenia and in their healthy siblings
Paola Bucci, Armida Mucci, Giuseppe Piegari, Maria Nobile, Stefano Pini, Alessandro Rossi, Antonio Vita, Silvana Galderisi, Mario Maj
Schizophrenia Research, Volume 174, Issue 1-3, July 2016, Pages 172 - 176
Impact of early intervention services on duration of untreated psychosis: Data from the National EDEN prospective cohort study
Max Marshall, Nusrat Husain, Natalie Bork, Imran B. Chaudhry, Helen Lester, Linda Everard, Swaran P. Singh, Nick Freemantle, Vimal Sharma, Peter B. Jones, David Fowler, Tim Amos, Barbara Tomenson, Max Birchwood
Schizophrenia Research, 1, 159, pages 1 - 6
Daniel Casey, Luke Brown, Ruchika Gajwani, Zoebia Islam, Rubina Jasani, Helen Parsons, Priya Tah, Max Birchwood, Swaran P. Singh
Schizophrenia Research, In Press, Corrected Proof, Available online 25 April 2016, Available online 25 April 2016
Adolescent vs. adult onset of a first episode psychosis: Impact on remission of positive and negative symptoms
Franz Veru, Gerald Jordan, Ridha Joober, Ashok Malla, Srividya Iyer
Schizophrenia Research, Volume 174, Issue 1-3, July 2016, Pages 183 - 188